Note 9 - Patents - Summary of Patents (Details) - USD ($) |
Sep. 30, 2018 |
Dec. 31, 2017 |
|---|---|---|
| Patents, cost | $ 4,017,510 | $ 4,017,510 |
| Patents, impairment | (1,539,794) | |
| Patents, accumulated amortization | (2,029,188) | (1,227,762) |
| Patents, net | 448,528 | 2,789,748 |
| Foundation Intellectual Property Patents [Member] | ||
| Patents, cost | 1,377,863 | 1,377,863 |
| Patents, impairment | ||
| Patents, accumulated amortization | (929,335) | (787,821) |
| Patents, net | 448,528 | 590,042 |
| Epidural-Apad Patents [Member] | ||
| Patents, cost | 2,639,647 | 2,639,647 |
| Patents, impairment | (1,539,794) | |
| Patents, accumulated amortization | (1,099,853) | (439,941) |
| Patents, net | $ 2,199,706 |
| X | ||||||||||
- Definition The accumulated amount of impairment loss recognized resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. No definition available.
|
| X | ||||||||||
- Definition Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|